{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","spread":"0.0","upperLimit":"30.8","value":"0.0"},{"groupId":"OG001","lowerLimit":"1.2","spread":"1.2","upperLimit":"31.7","value":"10.0"},{"groupId":"OG002","lowerLimit":"0.0","spread":"0.0","upperLimit":"30.8","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with BOR of CR or PR based on investigator assessment according to RECIST version 1.1 for non-HGG cohorts and RANO for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \\<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with recurrent or refractory ewing sarcoma received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG000","title":"Phase 2: Cohort 1, Ewing Sarcoma"},{"description":"Participants with recurrent or refractory rhabdomyosarcoma received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG001","title":"Phase 2: Cohort 2, Rhabdomyosarcoma"},{"description":"Participants with recurrent or refractory HGG received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG002","title":"Phase 2: Cohort 3, HGG"}],"paramType":"NUMBER","populationDescription":"Evaluable analysis set included all evaluable participants who have measurable disease present at baseline, and at least one postbaseline efficacy assessment, unless they have discontinued prior to the first efficacy assessment due to progressive disease.","reportingStatus":"POSTED","timeFrame":"From the date of the first dose of study drug to the date of first documentation of disease progression or death, which ever occurred first (up to 6.5 months)","title":"Phase 2: Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}